147 related articles for article (PubMed ID: 38626012)
41. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
[TBL] [Abstract][Full Text] [Related]
42. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
Wong RJ; Liu B; Bhuket T
Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
[TBL] [Abstract][Full Text] [Related]
43. Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study).
Collier A; Curran C; Cameron L; Wild SH; Byrne CD
Diabetes Obes Metab; 2023 Sep; 25(9):2659-2668. PubMed ID: 37311724
[TBL] [Abstract][Full Text] [Related]
44. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
Nah EH; Cho S; Park H; Noh D; Kwon E; Cho HI
PLoS One; 2021; 16(11):e0260477. PubMed ID: 34818372
[TBL] [Abstract][Full Text] [Related]
45. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
[TBL] [Abstract][Full Text] [Related]
46. Psoriasis and Liver Damage in HIV-Infected Patients.
Busca Arenzana C; Quintana Castanedo L; Chiloeches Fernández C; Nieto Rodríguez D; Herranz Pinto P; Delgado Hierro AB; Olveira Martín A; Montes Ramírez ML
Cells; 2021 May; 10(5):. PubMed ID: 34064387
[No Abstract] [Full Text] [Related]
47. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV.
Milic J; Menozzi V; Schepis F; Malagoli A; Besutti G; Franconi I; Raimondi A; Carli F; Mussini C; Sebastiani G; Guaraldi G
AIDS; 2020 Nov; 34(13):1915-1921. PubMed ID: 33009010
[TBL] [Abstract][Full Text] [Related]
48. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
49. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.
Nickel F; Tapking C; Benner L; Sollors J; Billeter AT; Kenngott HG; Bokhary L; Schmid M; von Frankenberg M; Fischer L; Mueller S; Müller-Stich BP
Obes Surg; 2018 May; 28(5):1342-1350. PubMed ID: 29119336
[TBL] [Abstract][Full Text] [Related]
50. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
[TBL] [Abstract][Full Text] [Related]
51. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
[TBL] [Abstract][Full Text] [Related]
52. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
[TBL] [Abstract][Full Text] [Related]
53. MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.
Cheung JTK; Zhang X; Wong GL; Yip TC; Lin H; Li G; Leung HH; Lai JC; Mahadeva S; Nik Mustapha NR; Wang XD; Liu WY; Wong VW; Chan WK; Zheng MH
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1194-1204. PubMed ID: 37724633
[TBL] [Abstract][Full Text] [Related]
54. Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study.
Mettananda C; Egodage T; Dantanarayana C; Fernando R; Ranaweera L; Luke N; Ranawaka C; Kottahachchi D; Pathmeswaran A; de Silva HJ; Dassanayake AS
BMJ Open; 2023 Jan; 13(1):e063959. PubMed ID: 36639212
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
Zhang X; Heredia NI; Balakrishnan M; Thrift AP
PLoS One; 2021; 16(6):e0252164. PubMed ID: 34081733
[TBL] [Abstract][Full Text] [Related]
56. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
57. Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes.
Lundholm MD; Bena J; Zhou K; Tsushima Y; Kashyap SR
J Diabetes Complications; 2023 Feb; 37(2):108405. PubMed ID: 36669324
[TBL] [Abstract][Full Text] [Related]
58. A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy.
Cervoni JP; Alby-Lepresle B; Weil D; Zhong P; Aubin F; Wendling D; Toussirot E; Vuitton L; Carbonnel F; Blondet R; Thévenot T; Calès P; Monnet E; Di Martino V
Clin Res Hepatol Gastroenterol; 2020; 44S():100003. PubMed ID: 33602481
[TBL] [Abstract][Full Text] [Related]
59. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.
Park JG; Jung J; Verma KK; Kang MK; Madamba E; Lopez S; Qas Yonan A; Liu A; Bettencourt R; Sirlin C; Loomba R
Aliment Pharmacol Ther; 2021 May; 53(9):1030-1037. PubMed ID: 33764550
[TBL] [Abstract][Full Text] [Related]
60. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
